ALKSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Alkermes plc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026
$42.97+1.75 (+4.25%)
Close on Oct 19, 2026
- Market cap
- $7.45B
- P/E (TTM)
- 113.1
- Dividend yield
- –
Alkermes plc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales, net | $1.38B | $1.28B | $1.18B | $1.18B | $1.13B | $1.09B | $1.08B | $1.02B | $976.60M | $938.81M | $920.00M | $894.14M | 82.9% | +22.1% |
| VIVITROL | $482.14M | $479.35M | $467.91M | $477.91M | $470.44M | $460.65M | $457.32M | $425.57M | $411.22M | $401.42M | $400.42M | $400.02M | 28.9% | +2.5% |
| ARISTADA and ARISTADA INITIO | $385.82M | $390.39M | $370.04M | $369.44M | $356.04M | $340.79M | $346.19M | $332.94M | $330.12M | $326.48M | $327.69M | $323.55M | 23.1% | +8.4% |
| LYBALVI | $378.73M | $369.03M | $346.69M | $329.53M | $305.98M | $293.05M | $280.03M | $259.27M | $235.26M | $210.91M | $191.89M | $170.58M | 22.7% | +23.8% |
| Manufacturing and royalty revenues | $284.90M | $284.04M | $291.26M | $344.46M | $372.84M | $419.28M | $474.10M | $487.34M | $531.30M | $787.36M | $743.39M | $696.43M | 17.1% | -23.6% |
| Royalty | $247.83M | $251.30M | $245.26M | $248.61M | $269.83M | $312.56M | $354.67M | $389.54M | $408.83M | $653.27M | $600.89M | $554.73M | 14.9% | -8.2% |
| Manufacturing Revenue | $37.07M | $32.74M | $46.00M | $95.85M | $103.01M | $106.72M | $119.43M | $97.80M | $122.47M | $134.09M | $142.50M | $141.70M | 2.2% | -64.0% |
| Research and development revenue | – | – | – | $0 | $0 | $0 | $3.00K | $6.00K | $9.00K | $16.00K | $19.00K | $27.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Alkermes's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.